Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
Anais Brasileiros de Dermatologia · 2025
DOI: 10.1016/j.abd.2024.02.006 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Fikriye Kalkan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Electronic address: fikr…. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents, Cost-Benefit Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey. Electronic address: fikriyehandan@gmail.com.
- Department of Immunology and Allergy, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Zitieren
APA
Kalkan, F., Yeşillik, S., Demirel, F., Sönmez, E., Balaban, Y., İnan, M. İ., & Kartal, Ö. (2025). Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.02.006
Vancouver
Kalkan F, Yeşillik S, Demirel F, Sönmez E, Balaban Y, İnan Mİ, et al. Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.02.006
BibTeX
@article{Kalkan2025,
author = {Kalkan, Fikriye and Yeşillik, Sait and Demirel, Fevzi and Sönmez, Ezgi and Balaban, Yasemin and İnan, Mustafa İlker and Kartal, Özgür},
title = {Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria},
journal = {Anais Brasileiros de Dermatologia},
year = {2025},
doi = {10.1016/j.abd.2024.02.006}
}
EUVIMED